CT Antigen TCR-Engineered T Cells for Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 15, 2013

Primary Completion Date

December 10, 2014

Study Completion Date

April 9, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Treatment with NY-ESO-1c259-modified T cells

"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."

Trial Locations (2)

21201

Greenebaum Cancer Center, University of Maryland, Baltimore

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Adaptimmune

INDUSTRY

NCT01892293 - CT Antigen TCR-Engineered T Cells for Myeloma | Biotech Hunter | Biotech Hunter